SEC Tracker
Get the app

Renovaro LNAI

Renovaro Q1 FY25: net loss $44.2M; diluted EPS −$0.28

Form
10-Q/A
Filed
Period
Importance
Routine
Document
10-Q/A

Key figures from this report

These are the numbers Renovaro reported for Q1 FY25, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$44.2MAgainst −$9.2M in Q1 FY2410-Q/A income statement, on EDGAR
  2. Diluted EPS−$0.28Against −$0.14 in Q1 FY2410-Q/A income statement, on EDGAR
  3. Cash and cash equivalents$221K−58% from $523K in Q1 FY2410-Q/A balance sheet, on EDGAR
  4. Cash from operations−$2.0MAgainst −$2.8M in Q1 FY2410-Q/A cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Renovaro files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Dare Bioscience DARE public float $21M, Jun 30, 2025
  2. Imunon IMNN public float $21M, Jun 30, 2025
  3. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  4. Fibrogen FGEN public float $21M, Jun 30, 2025
  5. Aptose Biosciences APTOF public float $22M, Jun 28, 2025